de Weers O, Beurret M, van Buren L, Oomen L A, Poolman J T, Hoogerhout P
National Institute of Public Health and the Environment (RIVM), Laboratory of Vaccine Development and Immune Mechanisms, The Netherlands.
Bioconjug Chem. 1998 May-Jun;9(3):309-15. doi: 10.1021/bc9702011.
Pneumococcal polysaccharide type 6B, 14, or 23F (35-70 kDa) was activated with cyanogen bromide and modified with cystamine. After reduction of the spacer, the thiol-containing (i.e. cysteamine-modified) polysaccharide obtained was added in a 5-10-fold molar excess to bromoacetylated tetanus toxoid to give thioether-linked polysaccharide-protein conjugates in a yield of 10-20%. This approach failed for preparing a type 19F polysaccharide-protein conjugate, possibly due to intramolecular elimination of cysteamine from the reduced 19F polysaccharide. When N,N'-bis(glycyl)cystamine was introduced as a spacer molecule, the elimination of the reduced spacer was suppressed, thus allowing preparation of a 19F polysaccharide-tetanus toxoid conjugate (15%).
6B、14或23F型肺炎球菌多糖(35 - 70 kDa)用溴化氰活化,并用胱胺进行修饰。在间隔物还原后,将得到的含硫醇的(即半胱胺修饰的)多糖以5至10倍的摩尔过量加入到溴乙酰化破伤风类毒素中,以10%至20%的产率得到硫醚连接的多糖-蛋白质缀合物。这种方法未能成功制备19F型多糖-蛋白质缀合物,可能是由于还原后的19F多糖分子内半胱胺的消除。当引入N,N'-双(甘氨酰)胱胺作为间隔分子时,还原间隔物的消除受到抑制,从而能够制备19F多糖-破伤风类毒素缀合物(产率15%)。